In Pfizer's case, the healthcare giant has a much broader scope of drugs in its portfolio. It even has a whole segment related to oncology -- which Seagen focuses on. At the time Pfizer announced the deal, it noted that it had 24 "approved innovative cancer medicines" and that by combining with Seagen, its early-stage oncology pipeline would double.